lercea glp-1 nano microneedle patch 𝑳𝒆𝒓𝒄𝒆𝒂® 𝐍𝐈𝐃𝐃𝐊-𝐓𝐢𝐫𝐳𝐞𝐩𝐚𝐭𝐢𝐝𝐞 𝐒𝐥𝐢𝐦𝐦𝐢𝐧𝐠 & 𝐡𝐞𝐚𝐥𝐭𝐡 𝐍𝐀𝐍𝐎 𝐌𝐈𝐂𝐑𝐎𝐍𝐄𝐄𝐃𝐋𝐄 𝐏𝐀𝐓𝐂𝐇 𝑳𝒆𝒓𝒄𝒆𝒂® 𝐍𝐈𝐃𝐃𝐊-𝐓𝐢𝐫𝐳𝐞𝐩𝐚𝐭𝐢𝐝𝐞 𝐒𝐥𝐢𝐦𝐦𝐢𝐧𝐠 & 𝐡𝐞𝐚𝐥𝐭𝐡

On April 1, 2026, the FDA approved orforglirpon under the brand name Foundayo to reduce excess body weight and maintain weight reduction long term in: Adults with obesity Adults with overweight and at least one weight-related medical condition Like other GLP-1s for weight loss, orforglipron is also indicated in combination with a reduced-calorie diet and increased physical activity

Membership includes ongoing communication with licensed providers, nurse-led coaching, and an insurance concierge for cost support

Try to incorporate a combination of fruits, veggies, and good fats from things like nuts or avocados

Are allergic to semaglutide/tirzepatide or their ingredients

Metabolic impact of endogenously produced estrogens by adipose tissue

When prescribed and monitored by a provider, GLP-1 medications are generally safe and well-tolerated